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ORIGINAL ARTICLE
Comparison of vancomycin and linezolid in patients with peripheral
vascular disease and/or diabetes in an observational European study of
complicated skin and soft-tissue infections due to methicillin-resistant
Staphylococcus aureus
C. Eckmann1, D. Nathwani2, W. Lawson3, S. Corman4, C. Solem4, J. Stephens4, C. Macahilig5, J. Li6, C. Charbonneau7,
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1) Klinikum Peine, Academic Hospital of Medical University Hannover, Peine, Germany, 2) Ninewells Hospital and Medical School, Dundee, 3) Hammersmith
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Abstract
Suboptimal antibiotic penetration into soft tissues can occur in patients with poor circulation due to peripheral vascular disease (PVD) or
diabetes. We conducted a real-world analysis of antibiotic treatment, hospital resource use and clinical outcomes in patients with PVD
and/or diabetes receiving linezolid or vancomycin for the treatment of methicillin-resistant Staphylococcus aureus complicated skin and
soft-tissue infections (MRSA cSSTIs) across Europe. This subgroup analysis evaluated data obtained from a retrospective, observational
medical chart review study that captured patient data from 12 European countries. Data were obtained from the medical records of
patients  18 years of age, hospitalized with an MRSA cSSTI between 1 July 2010 and 30 June 2011 and discharged alive by 31 July 2011.
Hospital length of stay and length of treatment were compared between the treatment groups using inverse probability of treatment
weights to adjust for clinical and demographic differences. A total of 485 patients had PVD or diabetes and received treatment with
either vancomycin (n = 258) or linezolid (n = 227). After adjustment, patients treated with linezolid compared with vancomycin
respectively had signiﬁcantly shorter hospital stays (17.9 ± 13.6 vs. 22.6 ± 13.6 days; p < 0.001) and treatment durations (12.9 ± 7.9 vs.
16.4 ± 8.3 days; p < 0.001). The proportions of patients prescribed oral, MRSA-active antibiotics at discharge were 43.2% and 12.4% of
patients in the linezolid and vancomycin groups, respectively (p < 0.001). The reduction in resource use may result in lower hospital
costs for patients with PVD and/or diabetes and MRSA cSSTIs if treated with linezolid compared with vancomycin.
© 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases.
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Introduction
Patients with peripheral vascular disease (PVD) or diabetes are
at high risk of developing complicated skin and soft-tissue in-
fections (cSSTIs), and when they occur, these infections may be
more challenging to treat [1,2]. The ability of some antibiotics
to penetrate into soft tissues, especially the lower extremities,
can be compromised in these patients, resulting in lower
Clin Microbiol Infect 2015; 21: S33–S39
© 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
http://dx.doi.org/10.1016/j.cmi.2015.01.011
antibiotic concentrations at the infection site than in the plasma
[3]. Vancomycin, in particular, has been shown to distribute
poorly into the soft tissues of diabetic patients, which has been
hypothesized as a mechanism for treatment failures [2].
The clinical impact of suboptimal vancomycin penetration into
infected tissue is not well documented. Patients with vascular
disease given vancomycin for culture-proven methicillin-resistant
Staphylococcus aureus (MRSA) cSSTIs had lower clinical success
rates (p 0.02) than patients receiving linezolid in a subgroup
analysis of pooled data from two clinical trials [1]. In contrast,
patients with diabetes mellitus given linezolid or vancomycin for
culture-proven MRSA cSSTIs had similar clinical success rates in a
subgroup analysis of data from three clinical trials [2].
To our knowledge, the effects of an antibiotic regimen on
outcomes in patients with MRSA cSSTIs and comorbid PVD or
diabetes mellitus have not been evaluated in a real-world
setting. Therefore, we conducted a real-world analysis of anti-
biotic treatment, hospital resource use, and clinical outcomes in
patients with PVD and/or diabetes receiving linezolid or van-
comycin for the treatment of MRSA cSSTIs across Europe.
Materials and methods
This subgroup analysis evaluated data obtained from a retro-
spective, observational medical chart review study that
captured patient information via 342 physicians in 12 European
countries (the UK, Ireland, France, Germany, Italy, Spain,
Portugal, Austria, Greece, Poland, Slovakia and the Czech Re-
public) [4–6]. Data were obtained from hospital records of
patients aged 18 years of age or older who were hospitalized
with a documented MRSA cSSTI between 1 July 2010 and 30
June 2011 and discharged alive by 31 July 2011. Patients were
excluded from the study if they had suspected or proven dia-
betic foot infection, osteomyelitis, infective endocarditis, men-
ingitis, joint infection, necrotizing fasciitis, gangrene, prosthetic
joint infection or prosthetic implant/device infection, or signif-
icant concomitant infection at other sites (e.g. bacteraemia,
pneumonia). To be included in this subgroup analysis, patients
had to have received MRSA-targeted therapy with vancomycin
or linezolid for the full duration of antibiotic therapy, either as
monotherapy or in combination with other antibiotics.
Study investigators randomly selected hospital records for
review for patients meeting the enrolment criteria. Data
collected included demographic and clinical characteristics,
MRSA-targeted intravenous (IV) and oral antibiotic use, hospital
resource use and clinical outcomes. Additionally, records of
patients with MRSA cSSTIs and PVD treated with linezolid were
oversampled so as to have a sufﬁcient sample size for
comparisons.
Study investigators identiﬁed patients with PVD and/or dia-
betes following review of the patient’s medical chart. The full
analysis set for this sub-study included patients with PVD, dia-
betes, or both. The PVD analysis set included only patients with
PVD, regardless of whether or not they had diabetes. The
lower extremity cSSTI analysis set included all of the patients in
the PVD analysis set who had a lower extremity cSSTI (foot,
toes, leg or groin).
The primary outcome was hospital length of stay (LOS; total
and by type of hospital unit). Secondary outcomes included
MRSA-targeted antibiotic length of treatment (LOT; total and
IV) and number of cSSTI-associated surgical procedures
required during hospitalization. Clinical response at discharge
was evaluated and deﬁned as cure (resolution of all signs and
symptoms/improvement to such an extent that further anti-
microbial therapy was not necessary), improvement
(improvement in signs and symptoms), failure (persistence,
incomplete clinical resolution, or worsening in signs and
symptoms), or indeterminate (inability to determine an
outcome).
The primary study comparison was between vancomycin-
and linezolid-treated patients. Inverse probability of treatment
weights based on propensity scores were used to adjust for
demographic and clinical differences between patients receiving
these antibiotics. Variables used to construct the inverse
probability of treatment weights included patient demographics
(age, gender, race, body mass index, smoking history, intrave-
nous drug abuse, alcohol use), clinical characteristics (diagnoses
(PVD, diabetes, or both), comorbid conditions, cSSTI type,
cSSTI source, cSSTI location, co-infection, MRSA infection
within the past 12 months, previous MRSA infection, time to
MRSA-targeted therapy), and hospital characteristics (type of
hospital, location, early discharge protocol, discharge physician
type). Weighted groups were compared using Pearson’s chi-
square test for categorical or ordinal characteristics and a t
test for continuous characteristics. All inferences were made
assuming a two-sided test with an α 0.05.
Results
The parent study cohort included a total of 1542 patients with a
documented MRSA cSSTI (Fig. 1). This subgroup analysis
included data from 485 patients with a documented MRSA
cSSTI and PVD and/or diabetes treated with linezolid or van-
comycin for the full duration of therapy.
Patients with PVD and/or diabetes
A total of 258 patients received vancomycin and 227 patients
received linezolid. Although differences in demographic and
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clinical characteristics between these two treatment groups
were identiﬁed (Table 1), they were not statistically signiﬁcant
after propensity-score-based weights were applied.
Overall hospital LOS was more than 4 days shorter in
linezolid-treated patients (17.9 ± 13.6 days) compared with
vancomycin-treated patients (22.6 ± 13.6 days) with MRSA
cSSTIs and PVD and/or diabetes (p < 0.001; Fig. 2). The dif-
ference in hospital LOS was driven primarily by a signiﬁcant
reduction in general ward LOS in linezolid-treated patients
(13.9 days) compared with vancomycin-treated patients (18.2
days) (p < 0.001). Additionally, both total (p < 0.001) and IV
(p < 0.001) LOT, respectively, were >3 days shorter in
linezolid-treated patients (12.9 ± 7.9 days and 12.7 ± 7.8 days)
compared with vancomycin-treated patients (16.4 ± 8.3 days
and 16.4 ± 8.4 days) (Fig. 3).
Although signiﬁcantly more patients receiving linezolid
(46.2%) than vancomycin (34.6%) underwent any surgical pro-
cedure (p 0.009), the number of procedures per patient was
not signiﬁcantly different between groups (p 0.069). Clinical
success rates at discharge (deﬁned as cure or improvement)
were >99% in both groups.
Patients with PVD, with or without diabetes
Of the 485 patients with PVD and/or diabetes, 300 patients had
PVD and received either vancomycin (n = 134) or linezolid
(n = 166) therapy for the full duration of treatment. Signiﬁcant
between-group differences existed for age, prevalence of co-
morbid diabetes, Charlson Comorbidity Index, cSSTI source,
prevalence of co-infection, previous MRSA infections, hospital
type and location, discharge physician type, and prevalence of
severe sepsis before propensity-score weighting. Only the
prevalence of comorbid diabetes (vancomycin 43.1%, linezolid
31.6%; p 0.039) and prevalence of severe sepsis (vancomycin
15.6%, linezolid 6.3%; p 0.010) remained unbalanced between
treatment groups following propensity-score weighting.
Hospital LOS was >4 days shorter in linezolid-treated pa-
tients (17.5 ± 12.3 days) compared with vancomycin-treated
patients (22.1 ± 14.0 days) with PVD (p 0.002; Fig. 4). Simi-
larly, linezolid-treated patients compared with vancomycin-
treated patients respectively had shorter antibiotic LOT
(13.6 ± 8.2 vs. 16.1 ± 7.6 days; p 0.006) and IV LOT (13.3 ± 8.2
vs. 16.1 ± 7.7 days; p 0.003). Total LOT and IV LOT were
similar in both groups, with a few patients switching from IV to
FIG. 1. Cohort selection for patient subgroup with methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft-tissue infections and
peripheral vascular disease (PVD) and/or diabetes.
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oral therapy during hospitalization (one patient in the vanco-
mycin group and seven patients in the linezolid group). How-
ever, of the 227 patients who received IV linezolid while
hospitalized, 98 (43.2%) received an oral, MRSA-active
discharge antibiotic, of which 80 (81.6%) were linezolid. In
contrast, of the 258 patients receiving vancomycin while hos-
pitalized, only 32 (12.4%) received a discharge prescription for
an oral, MRSA-active antibiotic (p < 0.001).
A similar proportion of patients receiving linezolid (36.6%)
and vancomycin (36.6%) underwent a surgical procedure (p
0.736); the number of procedures per patient did not differ
between the linezolid (1.1 procedures) and vancomycin (1.1
procedures) treatment groups (p 0.346). Clinical success rates
also did not differ between groups (p 0.773).
Patients with PVD and a lower extremity MRSA cSSTI,
with or without diabetes
Of the 300 patients with PVD, 198 (66%) had a lower extremity
cSSTI and received either vancomycin (n = 94) or linezolid
(n = 104) for the full duration of therapy. Before weighting,
FIG. 2. Hospital length of stay in patients with methicillin-resistant
Staphylococcus aureus complicated skin and soft-tissue infections and
peripheral vascular disease and/or diabetes receiving vancomycin or
linezolid (propensity-score weighted). HDU, high-dependency unit;
ICU, intensive care unit.
FIG. 3. Total and intravenous length of treatment in patients with
methicillin-resistant Staphylococcus aureus complicated skin and soft-
tissue infections and peripheral vascular disease and/or diabetes
receiving vancomycin or linezolid (propensity-score weighted).
FIG. 4. Hospital length of stay in patients with methicillin-resistant
Staphylococcus aureus complicated skin and soft-tissue infections and
peripheral vascular disease receiving vancomycin or linezolid (pro-
pensity-score weighted). HDU, high dependency unit; ICU, intensive
care unit.
TABLE 1. Demographic and clinical characteristics of patients
with peripheral vascular disease and/or diabetes by methicillin-






(n [ 227) p
Male, % 58.5 60.8 0.612
Age at hospital admission,
years, mean ± SD
65.7 ± 12.7 64.2 ± 13.9 0.202
Body mass index, % 0.039
<18.5 kg/m2 (underweight) 2.3 0.4
18.5–24.9 kg/m2 (normal) 22.5 22.9
25–30 kg/m2 (overweight) 36.4 30.8
>30 kg/m2 (obese) 15.5 12.0
Undocumented 23.3 33.9
Intravenous drug abuse, % 3.9 4.4 0.770
Diagnosis, % <0.001
Diabetes 48.1 26.9
Peripheral vascular disease 26.4 52.0
Both 25.6 21.1




cSSTI, type % 0.041
Infected wound or ulcer 31.8 35.2
Deep/extensive cellulitis 22.1 22.9
Major abscess 19.0 12.8
Surgical site infection 13.2 8.4
Posttraumatic wound infection 11.6 14.1
Infected burn 2.3 6.6
cSSTI, site % 0.015
Lower extremity 67.1 56.4
Torso/abdomen 23.6 25.5
Upper extremity 7.0 12.3
Head/skull/neck 2.3 5.7
Severe sepsis, % 22.5 10.6 <0.001
Abbreviation: cSSTI, complicated skin and soft-tissue infection; SD, standard
deviation.
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there were signiﬁcant between-group differences in the prev-
alence of comorbid diabetes, Charlson Comorbidity Index,
cSSTI source, prevalence of co-infection, previous MRSA in-
fections, hospital type and location, discharge physician type and
prevalence of severe sepsis. Only the prevalence of severe
sepsis (vancomycin 14.5%, linezolid 4.1%; p 0.012) remained
unbalanced between treatment groups after weighting.
Hospital LOS was numerically shorter in linezolid-treated
patients (17.8 ± 14.0 days) compared with vancomycin-
treated patients (20.3 ± 11.6 days) with PVD and a lower ex-
tremity MRSA cSSTI (p 0.171); LOS by type of hospital unit did
not differ signiﬁcantly between groups. Both total (p 0.215) and
IV LOT (p 0.179), respectively, were not signiﬁcantly different
between patients receiving linezolid (13.7 ± 9.6 and 13.5 ± 9.8
days) and those receiving vancomycin (15.1 ± 6.3 and 15.0 ± 6.4
days).
There was no difference in the proportion of patients
requiring surgery (p 0.736) or the number of surgeries per
patient (p 0.985) between linezolid-treated and vancomycin-
treated patients with PVD and a lower extremity MRSA cSSTI
(data not shown).
Discussion
Among patients hospitalized with an MRSA cSSTI and PVD or
diabetes, hospital LOS and LOT were over 4 days and 3 days
shorter, respectively, in patients who received linezolid
compared with vancomycin. Patients who received linezolid
were over three times more likely to be discharged with an
oral MRSA-active antibiotic, which suggests that patients in the
linezolid group were discharged earlier to complete oral
therapy at home, whereas patients receiving vancomycin
remained in the hospital until the course of therapy was
completed.
Evidence from clinical trials enrolling patients with MRSA
cSSTIs suggests poorer outcomes in patients with PVD and/or
diabetes mellitus compared with patients without these con-
ditions [1,2]. Among patients with these comorbidities, the
effects of antibiotic selection on outcomes in patients with
MRSA cSSTIs had not been evaluated in a real-world study. We
found that patients with PVD and/or diabetes treated with
linezolid compared with vancomycin for an MRSA cSSTI had a
3-day shorter LOT and 4-day shorter hospital LOS, but similar
rates of clinical cure or improvement, after adjusting for patient
demographic and clinical characteristics using propensity-score
weights. The clinical cure rates at discharge in both groups
were 100% and 99.4%, much higher than those from clinical
trials with cSSTIs due to MRSA [2]. These very high rates of
clinical cure may have been inﬂuenced by the fact that many
patients in this retrospective review have been treated in
hospital until they clinically improved or they were cured. This
is reﬂected by the long overall LOS. Moreover, patients who
died in the hospital were excluded. The number of surgical
procedures required was similar for vancomycin-treated and
linezolid-treated patients. Similar results were seen when the
analysis was limited to patients with PVD but not when we
limited the population to those with PVD and lower extremity
infection. The non-signiﬁcant decrease in LOT and LOS in pa-
tients with PVD and lower extremity infection between the
linezolid and vancomycin treatment groups could be explained
by a loss of power when comparing differences within this
smaller subgroup.
One component essential to the successful treatment of
MRSA cSSTIs is attainment of pharmacologically active antibi-
otic concentrations at the site of infection [7]. Suboptimal
antibiotic tissue concentrations in infected tissue are hypothe-
sized to be an important cause of treatment failure. Impairment
of drug penetration into infected tissue was observed for many
types of infections including SSTIs [8]. Analysis of tissue pene-
tration studies is complicated by differences in methods used to
measure tissue penetration. For example, studies using skin
blister ﬂuid sampling and tissue biopsy specimens provide in-
formation on total drug concentrations whereas in vivo micro-
dialysis studies provide information on only unbound drug. As
only unbound and not bound drug is pharmacologically active,
only study results using unbound drug concentrations are
summarized below.
Vancomycin concentrations were lower in tissue than in
plasma in a study conducted in patients following cardiac sur-
gery [3]. Tissue concentrations were even lower in patients
with compared with those without diabetes. In this study,
vancomycin tissue concentrations were determined using in vivo
microdialysis in six patients with and six patients without dia-
betes following cardiac surgery. Patients received vancomycin
at a dose of 80–120 mg/h; tissue concentrations were
measured on day 8 ± 4 of treatment. Vancomycin tissue con-
centrations in both patients with and without diabetes were
lower than plasma concentrations. Vancomycin tissue concen-
trations were lower in patients with diabetes than those
without. The authors speculated that insufﬁcient tissue con-
centrations could contribute to treatment failure and antimi-
crobial resistance in patients with diabetes. Other proposed
mechanisms for impaired tissue penetration in patients with
diabetes include changes in vancomycin plasma protein binding
[3] and local and systemic inﬂammation [9].
In contrast, there appears to be little difference between
linezolid tissue and plasma concentrations in patients with
diabetes [10,11]. Linezolid steady-state tissue concentrations
determined using in vivo microdialysis in three patients with
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diabetes and severe bacterial lower limb infections were similar
to plasma and bone concentrations within 1 h of initiating a
linezolid infusion, indicating rapid and complete linezolid
penetration into the interstitial space [10]. Inﬂammation did not
inﬂuence the linezolid interstitial concentration in soft tissue.
Linezolid steady-state tissue concentrations determined using
in vivo microdialysis in nine patients with diabetes and chronic
lower limb infections were similar in infected and healthy
subcutaneous tissue [11]. Penetration ratios (area under the
curve (AUC)tissue/free AUCplasma) were similar for healthy thigh
tissue (1.42) and wound tissue (1.27; p 0.648). One additional
study using microdialysis reported lower linezolid tissue con-
centrations compared with plasma concentrations [12]. How-
ever, this study was not conducted at steady state.
Results from the vancomycin [3] but not the linezolid [10,11]
microdialysis studies suggest the possibility of suboptimal drug
concentrations at the site of infection in patients with MRSA
cSSTIs and diabetes. Because of the retrospective nature of this
study, we were not able to evaluate the effect of vancomycin
MIC on outcome. Lower vancomycin tissue concentrations
could have more of an effect in patients with MRSA isolates that
have a MIC greater than 1–2 mg/L. Study results suggest that
even small increases in vancomycin MICs can affect clinical ef-
ﬁcacy [13]. Future studies should evaluate the effect of vanco-
mycin MICs on clinical outcomes in patients with MRSA cSSTIs
and PVD and/or diabetes.
In addition to those described above, limitations of this study
include the inclusion of only hospitalized patients and the
exclusion of patients who died in the hospital. These selection
criteria were essential for the parent study, which aimed to
identify opportunities for early switch from IV to oral antibi-
otics (so necessitating the inclusion of only hospitalized pa-
tients) and early hospital discharge (so requiring the inclusion of
only patients discharged alive) among patients with MRSA
cSSTIs. As a result of the oversampling of patients with PVD
receiving linezolid, the results of the study do not reﬂect
practice patterns related to drug selection in the countries
studied. Finally, information about adjunctive therapies such as
wound dressings and use of hyperbaric oxygen was not
collected, and could have inﬂuenced outcomes if these thera-
pies were used more frequently in one of the groups. In addi-
tion, we did not evaluate the timing of surgical procedures in
relation to the initiation of antibiotic therapy, and we are
therefore unable to determine whether the greater proportion
of patients undergoing surgical procedures in the vancomycin
group can be attributed to failure of antibiotic therapy.
In conclusion, patients with MRSA cSSTIs and PVD and/or
diabetes receiving linezolid compared with vancomycin expe-
rience a shorter LOT and hospital LOS, which may ultimately
lead to a reduction in hospital costs.
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